Press Releases

EpiCypher Launches Novel, Affordable DNA Methylation Sequencing Assays to Accelerate Drug Discovery

EpiCypher® has announced the launch of CUTANA® meCUT&RUN and Multiomic CUT&RUN, two novel DNA methylation sequencing technologies advancing the frontiers of genomic research and drug discovery.

Aplos Analytics Expands Cloud-Based Platform to Include Custom Outputs

Aplos NCA includes new features to support custom data processing, flexible table and figure creation, and the ability to create custom reports using user-defined templates.

Mundipharma announces availability of REZZAYO® (rezafungin) for adult patients with invasive candidiasis following Health Service Executive reimbursement agreement1

Two New Clinical Studies Demonstrate Accuracy of Viz.ai Algorithm for Intracranial Hemorrhage Volume Measurements to Advance Timely, Critical Treatment Decisions

Real-world evidence supports Viz ICH Plus for reliable volume and midline shift estimation

Phenomix Sciences and Mayo Clinic to Present Landmark Research at DDW 2025, Advancing Precision Obesity Medicine

The extensive body of research from Mayo Clinic emphasizes major advancements in obesity, including prediction of GLP-1 side effects, a new obesity sub-phenotype, and insights into personalized bariatric and endoscopic procedures.

Symbiosis Earns Recognition from EcoVadis for Commitment to Sustainability

Symbiosis Pharmaceutical Services, a specialist sterile manufacturing CMO, who has been formally recognised by EcoVadis for its continued commitment to sustainability.

VieCure Integrates NCCN Content into Leading Technology Platform for Community Oncology Care

VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform

CluePoints’ Technology Named as Finalist in 2025 Citeline Awards

CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.

Innovative Blood Testing Tech Could Spell the End of Needle Phobia

Meribel Pharma Solutions launches with big ambitions to elevate pharma services to new heights

The launch of a new mid-sized CDMO, Meribel Pharma Solutions, bringing together 10 manufacturing sites and 3 development centres across Europe. The team – including ex-Synerlab and Catalent leadership – aims to offer agile, high-quality solutions across OSD, sterile, and semi-solid manufacturing. Built on a strong legacy, the company is filling a much-needed niche in the market with centres of excellence in lyophilisation, preservative-free multidose tech, and more.

Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem

Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.

High Force Research Appoints Chief Commercial Officer to Drive Growth

High Force Research, a leading UK-based provider of specialist chemical R&D and manufacturing services has just appointed Dr. Nathalie Huther as its first-ever Chief Commercial Officer following a recent management buyout. This is a pivotal moment for the company, as it gears up to accelerate growth and deepen its presence in the pharmaceutical, biotech, and specialty chemicals markets. Nathalie brings 15+ years of commercial leadership experience across the chemical and life sciences sectors and will be steering High Force Research’s business development and market expansion strategy.

Evestia Clinical - the new brand identity for EMAS Pharma - launches today

EMAS Pharma has officially rebranded as Evestia Clinical, signaling a bold new chapter as a specialised Contract Research Organization (CRO) dedicated to oncology and rare disease clinical trials. With the backing of Kester Capital and a leadership team with a proven track record, Evestia Clinical is set to redefine the clinical research landscape by delivering agile, expert-driven solutions to biotech innovators worldwide. With a rapidly growing demand for faster, more adaptive trials in complex therapeutic areas, this transformation comes at a critical time for the industry. The new identity underscores the company’s commitment to accelerating life-changing therapies to market while strengthening its strategic partnerships with biotech firms globally.

Phastar Secures Finalist Spot at 2025 Citeline Awards

Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.

Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions

Cepheid and Oxford Nanopore Technologies announce new collaboration to develop an integrated sequencing workflow to advance infectious disease analysis.

Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell

News from Cellistic, which has launched its new Echo™-NK platform to support the production of off-the-shelf Natural Killer cell therapies. The platform offers a cost-effective, GMP-compliant solution for scaling iPSC-derived NK cells, aimed at treating cancers and autoimmune diseases. It also integrates Cellistic’s STAR-CRISPR and Pulse technologies to help speed up development, with several client projects already in progress.

ELRIG Appoints Dr Del Trezise as Chair

Phenomix Sciences Announces First Prospective Clinical Study of Semaglutide Using MyPhenome™ Test

Building on a decade of research and validation, study leverages precision, phenotype-guided treatment for enhanced patient outcomes on GLP-1s.

CDMO Upperton Continues Growth with the Appointment of Michael Mellor-Clark as Chief Commercial Officer.

Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with the appointment of Michael Mellor-Clark as Chief Commercial Officer (CCO).

Indivumed Celebrates Milestone of Its Patient-Centric R&D Platform: Numerous Novel Cancer Targets Discovered for First-in-Class Therapeutics

Indivumed is proud to announce major milestones achieved, cementing its position as a leading oncology R&D company.